Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease associated with a poor prognosis and high morbidity. Early diagnosis and complete tumor removal are still the principal factors extending life expectancy in PDAC patients. Here, the relationship of neurexophillin 1 (NXPH1) and NXPH2 expressions with clinicopathological parameters of PDAC was evaluated. Immunohistochemical analysis of NXPH1 and NXPH2 was performed in one tissue microarray of 96 surgical specimens, including normal pancreatic duct tissue (n = 5), PDACs at various stages of differentiation (n = 77), and pancreatic neuroendocrine tumors (n = 14). The intensity of both NXPH1 and NXPH2 staining was weak in only a small proportion of benign pancreatic ductal epithelial cells and was significantly higher in most PDAC specimens than in non-neoplastic pancreatic tissue specimens. However, no correlation of the expression of these PDAC biomarkers with tumor grades, T, N, and American Joint Committee on Cancer (AJCC) pathologic stages was established. Contrary to our expectation, the immunohistochemical results of NXPH1 and NXPH2 were inversely correlated with N stage in PDAC. NXPH1 and NXPH2 as PDAC biomarkers may be used to identify patients with this tumor, help delineate appropriate surgical margins, and identify lymph node metastasis in imaging studies.
Introduction
Of all malignancies in the human body, pancreatic cancer is one of the most lethal. In the United States, more than 45,000 new pancreatic cancer cases were diagnosed in 2014 (25) . In addition, the mortality rate was found to closely approximate the incidence even after tumor resection or medical treatment (10) . Pancreatic ductal adenocarcinoma (PDAC), arising from the exocrine duct, is currently one of the main types of pancreatic carcinoma (7) . Traditionally, endoscopic retrograde cholangiopancreatography (ERCP) is used to detect pancreatic head tumors and take tissue samples (27) . Esophagogastroduodenoscopy (EGD) with endoscopic ultrasound (EUS) has recently been developed to reveal tumors in more detail (25) . However, the complex anatomic structure and limited biopsy specimen size still make it difficult to discriminate between PDAC and pancreatic benign lesions, including chronic pancreatitis (6) . Although it might indicate the presence of PDAC, elevated circulating serum CA-19-9 is detectable for only a short period during tumor development (11, 16, 23) . On the other hand, the differences in therapies and prognoses between pancreatic neoplasms and non-neoplastic disease are very large, making treatment decisions for clinicians a challenge. Therefore, the development of useful biomarkers that differentiate benign from malignant lesions could significantly improve diagnostic accuracy.
Dystroglycan (DAG1), encoded by dag1, is a transmembrane protein involved in extracellular matrix assembly in muscle and brain tissue (17) . Neurexin Iα (NRXN1α) plays a role in directing aspects of synaptogenesis (synapse development) including extracellular signaling and intercellular adhesion (22) . DAG1 and NRXN1α are mutual proteins that act as receptor ligands (30) . Interactions of DAG1 with NRXN1 stimulate hematopoiesis (13) . Neurexophillin 1-3 (NXPH1-3), 29-kDa neuropeptides, bind to NRXN1α with a higher affinity than DAG1 (2, 21, 22) . Recently, Chellappa et al. (4) demonstrated the activation of regulatory T cells could suppress immune system and promote tumor growth in pancreatic adenocarcinomas. The combination of NXPH1 or 2 with NRXN1α has some effects on interfering the immune system and representing a negative prognostic factor in some cancers (8, 18, 29, 33) . Additionally, NRXN1α had been proved to stimulate angiogenesis which plays an important role on cancer development (12) . Therefore, we hypothesized NXPH1 and 2 might be oncogenic factors on PDAC development.
In this study, we evaluated the relationship between NXPH1 and 2 and PDAC development using NXPH1 and 2 immunohistochemistry to detect the presence of PDACs and highlight the tumor cell boundary. Our results demonstrated that the combination of NXPH1 and NXPH2 biomarkers with H&E stains can effectively discriminate PDACs from benign pancreatic disease.
Materials and Methods
The tissue microarray slide was bought from US Biomax, Inc. (Rockville, MD, USA) and consisted of samples from 5 adjacent normal pancreatic tissues, 77 patients with PDAC, and 14 patients with other pancreatic tumors. Of the 77 PDACs, 14 were well-differentiated, 47 were moderately differentiated, and 16 were poorly differentiated. The pathological diagnoses of these cases were reviewed by two experienced pathologists. All tumors were pathologically staged according to the 8 th edition American Joint Committee on Cancer (AJCC) staging system criteria. Adjacent normal pancreatic tissues were taken at least 2 cm from the neoplasm. The tissue microarray slide showed uniform staining of the original paraffin-embedded specimens. None of these patients had ever received radiation or chemotherapy before surgery.
Tissue microarray sections were de-waxed in xylene, rehydrated in alcohol, immersed in 3% hydrogen peroxide for 5 min to suppress endogenous peroxidase activity, heated (100°C, 30 min) in 0.01 mol/L sodium citrate buffer (pH 6.0) for antigen retrieval, rinsed 3 times (each for 5 minutes in phosphate buffered saline [PBS]), incubated for 1 h at room temperature with a polyclonal rabbit antihuman NXPH1 antibody (1:100, Biorbyt, Cambridge, United Kingdom) and a polyclonal rabbit anti-human NXPH2 antibody (1:100, Biorbyt, Cambridge, United Kingdom), each diluted in PBS, washed 3 times (each for 5 min in PBS), incubated with biotin-labeled secondary immunoglobulin (1:100, DAKO, Glostrup, Denmark) for 1 h at room temperature, washed 3 times, and incubated with 3-amino-9-ethylcarbazole (AEC) + substrate chromogen (DAKO, Glostrup, Denmark) at room temperature until the proteins (detected as red spots) were visible.
NXPH1 and NXPH2 immunostaining intensity was scored from 0 (absence of staining) to 1 (weak staining), 2 (moderate staining), or 3 (strong staining). Weak, moderate, and strong cytoplasmic staining indicated microscopic expression at magnification 40x, 10x, and 4x, respectively (29) . The percentage of tumor cells with cytoplasmic staining at each intensity was estimated and the immunostaining score (ranging from 0 to 300) was obtained by multiplying the immunostaining score by the percentage (32) . The final immunostaining score on each case of tissue microarray was decided on the average NXPH1 an NXPH2 immunostaining scores from two pathologists reading slides.
The immunostaining scores of NXPH1 and NXPH2 in PDAC specimens were compared to those in nonneoplastic pancreatic duct specimens. The data were compared between groups using the Student's t-test. A P-value of less than 0.05 was considered to be statistically significant. SigmaState software (Jandel Scientific, San Rafael, CA, USA) was used to perform Pearson Product Method correlation and paired t-test analysis of the relationships between these two biomarkers and clinicopathological parameters.
Results

Clinicopathological Characteristics
The 77 patients with PDAC were diagnosed as having AJCC pathological stage IA (n = 5), stage IB (n = 7), stage IIA (n = 17), stage IIB (n = 22), stage III (n = 14), and stage IV (n = 12).
NXPH1 Expression in PDACs
The immunohistochemical results of NXPH1 are shown in Table 1 and Fig. 1 . Only a small proportion of adjacent non-neoplastic pancreatic ductal epithelial cells were weakly positive for NXPH1. The average NXPH1 immunostaining score was 12.69 in normal pancreatic tissue, 110.83 in grade I, 129.89 in grade II, and 143.33 in grade III PDAC. Although NXPH1 expression did not correlate with tumor differentiation (P = 0.242, R = 0.138), the NXPH1 immunostaining score was significantly higher in PDACs (regardless of grade) than in nonneoplastic pancreatic ducts (Fig. 2) . Of all the T, N, M, and AJCC pathological stages of PDACs, only N stage showed inverse correlation with NXPH1 immunostaining score (P = 0.043).
NXPH2 Expression in PDACs
The average NXPH2 immunostaining score was 156.07 in grade I, 145.21 in grade II, and 155.63 in grade III PDAC. NXPH2 immunostaining score was higher in most PDACs than in non-neoplastic pancreatic ducts (Fig. 2) . However, the relationship between NXPH2 expression and tumor grade did not reach statistical significance (P = 0.988, R = 0.002). Similarly, no correlation of the average NXPH2 immunostaining score with T, M, and AJCC pathological stages was detected. However, the average NXPH2 immunostaining score was 166.97 for N0 stage and 129 for N1 stage. Advanced N stage was inversely and significantly correlated with lower NXPH2 immunostaining score (P=0.023, Table 2 , Fig. 1 ).
NXPH1 and NXPH2 Expression in PNECs
All PNECs showed higher NXPH1 and NXPH2 immunohistochemical staining than normal pancreatic ducts. NXPH1 immunostaining scores of PNECs were listed as follows: grade I: 165, grade II: 196 and grade III: 216. In addition, NXPH2 immunostaining scores were 169.29 in grade I, 164 in grade II and 147.93 in grade III PNECs (Table 3 ). The correlation between NXPH1 and NXPH2 expressions with tumor grading did not reach statistical significance.
Discussion
It is well known that many factors including life habits, environmental factors, chronic inflammation, and hereditary disturbances contribute to the development of pancreatic cancer. The major risk factors include diet, smoking, chronic pancreatitis, diabetes, and obesity for sporadic pancreatic malignancies (10); and genetic and epigenetic mutations of PRSS1 (28) , SPINK (5), CDKN2A (3), STK11 (20) , BRCA2 (24) , APC (10), and mismatch repair genes for familial pancreatic cancers (15, 26) . NXPH1 and NXPH2 act as hematopoietic stem cell modulators in some inflammatory diseases, such as inflammatory bowel disease (34) . In recent studies, immune system imbalance has been proved to be a critical factor in cancer development (19) . We successfully proved that NXPH1 and NXPH2 expression was higher in PDAC than in non-neoplastic pancreatic tissue. Therefore, NXPH1 and NXPH2 might possibly be related to the carcinogenesis of PDACs.
To distinguish well-differentiated PDAC from non-neoplastic pancreatic lesions in small biopsies 
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is very difficult based on hematoxylin and eosin (H&E) staining alone (6) . In our study, the immunostaining of NXPH1 and NXPH2 on H&E slides might help pathologists effectively improve diagnostic accuracy and accurately assess tumor clearance. Since the expressions of these biomarkers correlated with N stage, the tendency of low NXPH1 and NXPH2 expression in PDACs might imply lymph node metastasis. Although its role in pathogenesis is still unclear, hypermethylation of NXPH1 has been demonstrated to be a potential biomarker for tumor invasion and metastasis in breast cancer (9) . Hong et al. (14) also demonstrated the more frequent occurrence of NXPH1 methylation in high grade than in low grade intraductal papillary mucinous neoplasms. Our results revealed that overexpression of NXPH1 and NXPH2 might have some role in the early stage of PDAC development and that their down-regulation may induce tumor cell metastasis. The bi-directional effects of NXPH1 and NXPH2 in cancer cell development is still unclear. It is well-known that suppression of the immune system enhances tumor overgrowth and chemoresistance, and that the cytotoxic T cell response is a key factor opposing tumorigenesis (31) . Nevertheless, Bayne et al. demonstrated that myeloid-derived suppressor cells, including early myeloid progenitor cells and immature dendritic cells, stimulated by chemokines could effectively suppress T cell activation and help establish the tumor microenvironment in pancreatic cancer (1) . Therefore, we propose that NXPH1 and NXPH2 might play critical roles in the regulation of the anti-tumor immune system. Initially, NXPH1 and NXPH2 might interrupt the mobilization of hematopoietic progenitor cells, thereby weakening immune system function and inducing cancer cell development in PDACs. Subsequently, down-regulation of these proteins might stimulate hematopoietic stem cells and suppress the anti-tumor T cell response. However, more evidence is still needed to make that judgment.
In conclusion, higher NXPH1 and NXPH2 immunostaining scores were associated with carcinoma development, but inversely correlated with more advanced N stage in PDAC. Although the mechanisms of tumor progression and metastasis are still unknown, NXPH1 and NXPH2 can be used as satisfactory biomarkers for confirming tumor existence even in small biopsies and might help decide whether the tumor has been totally removed. In the future, because NXPH1 and NXPH2 have opposing roles in PDAC development, caution should be exercised in the application of pharmacological agents that target these factors.
